Biocryst Pharmaceuticals INC: insider trades · United States · SEC (Form 4)

About Biocryst Pharmaceuticals INC

BioCryst Pharmaceuticals, Inc. (ticker BCRX) is a U.S.-listed biotechnology company traded on NASDAQ in the United States, with a focused rare-disease strategy centered on hereditary angioedema (HAE) and selected adjacent programs. Founded in 1986 in Birmingham, Alabama, BioCryst later relocated its headquarters to Durham, North Carolina, where it is currently based. Over time, the company has evolved from a research-heavy biotech into a commercial-stage organization led by a core marketed product, while retaining a targeted pipeline of oral, small-molecule candidates. The company’s commercial engine is ORLADEYO (berotralstat), an oral, once-daily prophylactic therapy for HAE attacks. ORLADEYO is BioCryst’s key revenue driver and the main strategic asset around which the business is organized. Management continues to expand the product’s addressable market through label and formulation expansion efforts, including pediatric access initiatives. Beyond its lead franchise, BioCryst also advances earlier-stage programs, notably BCX17725 for Netherton syndrome, alongside other preclinical and early clinical assets. The portfolio has been streamlined over time, with some legacy programs discontinued or de-emphasized, reflecting a more disciplined capital allocation framework. From a competitive standpoint, BioCryst occupies a specialized but highly competitive HAE market, where patients and physicians can choose among multiple preventive or on-demand therapies. The company’s principal differentiator is convenience: an oral once-daily therapy can be attractive versus injectable alternatives, particularly in chronic prophylaxis. BioCryst also has an international footprint through commercial partnerships outside the United States, which extends ORLADEYO’s reach across multiple regions without requiring the company to build every market directly. Recent disclosures indicate solid commercial momentum, including strong 2025 ORLADEYO revenue growth and FDA acceptance of an NDA for ORLADEYO oral granules, a potential catalyst for pediatric expansion. BioCryst also announced the sale of its European ORLADEYO business, which suggests an ongoing portfolio optimization strategy and a sharper focus on the most value-accretive opportunities.